Tempus AI, Inc. (TEM) Gross Margin: 69.55%
Is Tempus AI, Inc.’s gross margin high or low?
Tempus AI, Inc.'s gross margin of 69.55% is 56% above its 5-year average of 44.45%, near the high end of its 5-year range (15.27%–69.64%).
As of Friday, June 12, 2026. 11.64% above its 12-month average of 62.30%.
TEM Gross Margin Chart
TEM Average Gross Margin Chart
TEM Current vs Average Gross Margin Chart
TEM Gross Margin Metrics
GROSS MARGIN
69.55%
GROSS MARGIN AVG TTM
62.30%
GROSS MARGIN AVG 3Y
54.75%
GROSS MARGIN AVG 5Y
44.45%
GROSS MARGIN AVG 10Y
41.80%
GROSS MARGIN AVG 15Y
41.80%
GROSS MARGIN AVG 20Y
41.80%
CURRENT VS TTM AVG
+11.64%
CURRENT VS 3Y AVG
+27.03%
CURRENT VS 5Y AVG
+56.46%
CURRENT VS 10Y AVG
+66.40%
CURRENT VS 15Y AVG
+66.40%
CURRENT VS 20Y AVG
+66.40%
TEM Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $8.65B | 69.55% | 62.30% | 54.75% | 44.45% |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 31.86% | 31.70% | 34.15% | 35.17% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.91B | 51.87% | 52.87% | 53.77% | 54.60% |
| Baxter International Inc. (BAX) | $10.58B | 30.11% | 33.76% | 35.72% | 36.84% |
| Hims & Hers Health, Inc. (HIMS) | $6.44B | 67.64% | 76.65% | 78.21% | 76.94% |
| Align Technology, Inc. (ALGN) | $12.64B | 67.68% | 69.16% | 69.73% | 70.75% |
| Solventum Corporation (SOLV) | $13.72B | 53.67% | 54.56% | 56.03% | 57.27% |
| Hologic, Inc. (HOLX) | $16.97B | 52.82% | 58.14% | 57.33% | 59.28% |
| 23andMe Holding Co. (ME) | $15.31M | 53.33% | 48.95% | 47.93% | 47.45% |
| Moderna, Inc. (MRNA) | $19.70B | -13.89% | 54.80% | 53.09% | 65.45% |
Gross Margin Analysis
Gross Margin
69.5%
(Revenue - COGS) / Revenue
Tempus AI, Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tempus AI, Inc. Gross Margin FAQ
- What is the gross margin for Tempus AI, Inc. (TEM)?
- The gross margin for TEM stock is 69.55%.
- Is Tempus AI, Inc.'s gross margin high or low?
- Tempus AI, Inc.'s gross margin of 69.55% is 56% above its 5-year average of 44.45%, near the high end of its 5-year range (15.27%–69.64%).
- What is the TTM average gross margin for Tempus AI, Inc. (TEM)?
- The TTM average gross margin for TEM stock is 62.30%.
- What is the 3Y average gross margin for Tempus AI, Inc. (TEM)?
- The 3Y average gross margin for TEM stock is 54.75%.
- What is the 5Y average gross margin for Tempus AI, Inc. (TEM)?
- The 5Y average gross margin for TEM stock is 44.45%.
- What is the 10Y average gross margin for Tempus AI, Inc. (TEM)?
- The 10Y average gross margin for TEM stock is 41.80%.
- What is the 15Y average gross margin for Tempus AI, Inc. (TEM)?
- The 15Y average gross margin for TEM stock is 41.80%.
- What is the 20Y average gross margin for Tempus AI, Inc. (TEM)?
- The 20Y average gross margin for TEM stock is 41.80%.
Tempus AI, Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 69.64% |
| 2024-12-31 | 54.96% |
| 2023-12-31 | 53.81% |
| 2022-12-31 | 40.60% |
| 2021-12-31 | 32.44% |
| 2020-12-31 | 15.27% |
| 2019-12-31 | 25.85% |
Related Metrics
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky